ReviewInfectious diseases and therapy2017
New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review.
Review in Infectious diseases and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial.Hepatology international · 2020Trial
- NLRX1 can counteract innate immune response induced by an external stimulus favoring HBV infection by competitive inhibition of MAVS-RLRs signaling in HepG2-NTCP cells.Science progress · 2021Article
- Combination of saikosaponin c and telbivudine synergistically enhances the anti-HBV activity.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Article
- Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease.Hepatology communications · 2019Article
- The As and Bs of HIV and Hepatitis Co-Infection.Tropical medicine and infectious disease · 2019Review
- Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development.Gastroenterology · 2019Review
- HIV, HCV and HBV: A Review of Parallels and Differences.Infectious diseases and therapy · 2018Review
- Article
- Towards HBV curative therapies.Liver international : official journal of the International Association for the Study of the Liver · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although current therapies can be successful at suppressing hepatitis B viral load, long-term viral cure is not within reach. Subsequent strategies combining pegylated interferon alfa with nucleoside/nucleotide analogues have not resulted in any major paradigm shift. An improved understanding of the hepatitis B virus (HBV) lifec ycle and virus-induced immune dysregulation has, however, revealed many potential therapeutic targets, and there are hopes that treatment of hepatitis B could soon be revolutionized. This review summarizes the current developments in HBV therapeutics-both virus directed and host directed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.